Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: A cross-sectional study

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Ng, Khai P ^a   Stringer, Stephanie J ^a,b   Jesky, Mark D ^a,b   Yadav, Punit ^a,b   Athwal, Rajbir ^a   Dutton, Mary ^a   Ferro, Charles J ^a,b   Cockwell, Paul ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; URIC ACID;

ADULT; AGE; ARTERIAL STIFFNESS; ARTICLE; ASYMPTOMATIC DISEASE; CAUCASIAN; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DRUG USE; ESTIMATED GLOMERULUS FILTRATION RATE; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; GOUT; HIGH RISK PATIENT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLYDIPSIA; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; RASH; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

ALLOPURINOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; VASCULAR STIFFNESS;

EID: 84897987830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091961     Document Type: Article

References (60)

1. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, et al. (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48: 1031-1036. (Pubitemid 44772704)
2. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, et al. (2005) Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. International journal of clinical practice 59: 1276-1282. (Pubitemid 43904496)
3. Freedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. American journal of epidemiology 141: 637-644.
4. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA : the journal of the American Medical Association 283: 2404-2410.
5. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, et al. (2008) Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clinical chemistry 54: 273-284. (Pubitemid 351302628)
6. Strasak AM, Kelleher CC, Brant LJ, Rapp K, Ruttmann E, et al. (2008) Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. International journal of cardiology 125: 232-239.
7. Edwards NL (2008) The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic journal of medicine 75 Suppl 5: S13-16.
8. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, et al. (2007) Relationship of uric acid with progression of kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation 50: 239-247.
9. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, et al. (2009) Uric acid and long-term outcomes in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation 53: 796-803.
10. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, et al. (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. American journal of kidney diseases : the official journal of the National Kidney Foundation 44: 642-650.
11. Syrjanen J, Mustonen J, Pasternack A (2000) Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 15: 34-42.
12. Li YL, Wang L, Li J, Huang Y, Yuan WM (2011) [The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies]. Zhonghua nei ke za zhi [Chinese journal of internal medicine] 50: 555-561.
13. Yelken B, Caliskan Y, Gorgulu N, Altun I, Yilmaz A, et al. (2012) Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clinical nephrology 77: 275-282.
14. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, et al. (2011) Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. Journal of the American Society of Nephrology : JASN 22: 1382-1389.
15. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, et al. (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical journal of the American Society of Nephrology : CJASN 5: 1388-1393.
16. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM (2011) Impact of allopurinol use on urate concentration and cardiovascular outcome. British journal of clinical pharmacology 71: 600-607.
17. Chue CD, Townend JN, Steeds RP, Ferro CJ (2010) Arterial stiffness in chronic kidney disease: causes and consequences. Heart 96: 817-823.
18. Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology 55: 1318-1327.
19. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, et al. (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439. (Pubitemid 29218240)
20. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, et al. (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. European heart journal 27: 2588-2605. (Pubitemid 44627304)
21. Stringer S, Sharma P, Dutton M, Jesky M, Ng K, et al. (2013) The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC nephrology 14: 95.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine 130: 461-470. (Pubitemid 29135798)
23. Wright JM, Mattu GS, Perry Jr TL, Gelferc ME, Strange KD, et al. (2001) Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor. Blood pressure monitoring 6: 161-165. (Pubitemid 32744590)
24. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, et al. (2009) Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertension research : official journal of the Japanese Society of Hypertension 32: 1079-1085.
25. Pucci G, Cheriyan J, Hubsch A, Hickson SS, Gajendragadkar PR, et al. (2013) Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. Journal of hypertension 31: 77-85.
26. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, et al. (2000) The influence of heart rate on augmentation index and central arterial pressure in humans. The Journal of physiology 525 Pt 1: 263-270. (Pubitemid 30311951)
27. Altman D (1999) Practical statistics for medical research. London: Chapman & Hall.
28. Kals J, Kampus P, Kals M, Zilmer K, Kullisaar T, et al. (2006) Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. American journal of hypertension 19: 902-908. (Pubitemid 46106988)
29. Touyz RM (2004) Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44: 248-252.
30. George J, Carr E, Davies J, Belch JJ, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114: 2508-2516. (Pubitemid 44901524)
31. Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Annals of internal medicine 131: 7-13. (Pubitemid 29310011)
32. Alderman MH, Cohen H, Madhavan S, Kivlighn S (1999) Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34: 144-150. (Pubitemid 29325733)
33. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, et al. (1999) Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 10: 391-397. (Pubitemid 29288237)
34. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM (2006) Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke; a journal of cerebral circulation 37: 1503-1507. (Pubitemid 44305733)
35. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD (2000) Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Annals of epidemiology 10: 136-143. (Pubitemid 30171270)
36. Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD, et al. (2006) Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187: 401-407. (Pubitemid 43963022)
37. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, et al. (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Archives of internal medicine 164: 1546-1551. (Pubitemid 38970476)
38. Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthritis and rheumatism 54: 2688-2696. (Pubitemid 44208638)
39. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, et al. (2000) Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36: 1072-1078.
40. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, et al. (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney international 65: 1009-1016. (Pubitemid 38251077)
41. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, et al. (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and thrombosis : a journal of vascular biology/American Heart Association 14: 1521-1528.
42. Mulder DJ, de Boer JF, Graaff R, de Vries R, Annema W, et al. (2011) Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis 218: 102-106.
43. Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, et al. (2008) Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197: 217-223. (Pubitemid 351273241)
44. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. The Journal of biological chemistry 269: 9889-9897. (Pubitemid 24196599)
45. Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, et al. (2012) Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et biophysica acta 1820: 663-671.
46. Agarwal V, Hans N, Messerli FH (2012) Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis. The Journal of Clinical Hypertension: no-no.
47. Schutte AE, Huisman HW, Oosthuizen W, van Rooyen JM, Jerling JC (2004) Cardiovascular effects of oral Supplementation of vitamin C, E and folic acid in young healthy males. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition 74: 285-293.
48. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR (1997) Combination oral antioxidant supplementation reduces blood pressure. Clinical science 92: 361-365. (Pubitemid 27163093)
49. Miller ER, 3rd, Appel LJ, Levander OA, Levine DM (1997) The effect of antioxidant vitamin supplementation on traditional cardiovascular risk factors. Journal of cardiovascular risk 4: 19-24. (Pubitemid 27286098)
50. Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, et al. (2004) Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arteriosclerosis, thrombosis, and vascular biology 24: 1485-1491. (Pubitemid 39050445)
51. Eskurza I, Monahan KD, Robinson JA, Seals DR (2004) Ascorbic acid does not affect large elastic artery compliance or central blood pressure in young and older men. American journal of physiology Heart and circulatory physiology 286: H1528-1534. (Pubitemid 38381164)
52. Mottram P, Shige H, Nestel P (1999) Vitamin E improves arterial compliance in middle-aged men and women. Atherosclerosis 145: 399-404. (Pubitemid 29359150)
53. Wray DW, Uberoi A, Lawrenson L, Bailey DM, Richardson RS (2009) Oral antioxidants and cardiovascular health in the exercise-trained and untrained elderly: a radically different outcome. Clinical science 116: 433-441.
54. Jia N, Dong P, Ye Y, Qian C, Dai Q (2012) Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction. Cardiovascular therapeutics 30: 117-123.
55. Ercan ZS, Ilhan M, Oguz A, Turker RK (1992) Superoxide dismutase and allopurinol prevent the pressor effects of angiotensin II and histamine in the guinea-pig isolated perfused lung exposed to hypoxia. General pharmacology 23: 1149-1151.
56. Kasal DA, Neves MF, Oigman W, Mandarim-de-Lacerda CA (2008) Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor. Histology and histopathology 23: 1241-1248.
57. Kostka-Jeziorny K, Uruski P, Tykarski A (2011) Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood pressure 20: 104-110.
58. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511. (Pubitemid 36158056)
59. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, et al. (2007) Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. International urology and nephrology 39: 1227-1233. (Pubitemid 350193621)
60. Siu Y-P, Leung K-T, Tong MK-H, Kwan T-H (2006) Use of Allopurinol in Slowing the Progression of Renal Disease Through Its Ability to Lower Serum Uric Acid Level. american journal of kidney diseases 47: 51-59.